

When it comes to CRISPR mice, what exactly is your deliverable?




The production of genetically modified mouse models is changing faster than ever thanks to CRISPR/Cas9 gene editing. With multiple approaches available for generating knockout or knockin mice, it is important to understand exactly what the deliverable is, and what needs to be done after receiving your mice.

Did you know that most CRISPR mouse production services are only guaranteeing founders for the timelines and costs quoted? Similar to transgenic pronuclear microinjection, founder mice that are genetically modified via CRISPR microinjection need to be bred for 1-2 generations to remove allelic and cellular mosaicism, and to confirm germline transmission prior to mice expansion and experimentation.

Cas9 editing may occur after the first round of zygote division and the CRISPR/Cas9 components will likely not be carried to all cells during division. This results in a founder mouse composed of cells with different gene editing events. If your desired editing event is not represented in the gametes of your founder, then germline transmission has not been achieved.

A deliverable of guaranteed founders does not mean that you will receive a germline confirmed mouse model. When exploring your options for creating a novel mouse line, be sure to ask, "[What deliverable does this guarantee cover?](#)"

Publications



Congrats Dr. Catherine C. Hedrick on another publication with a conditional *Abcg1* knockout mouse model created by ingenious! In their study published in *Journal of Clinical Investigation*, Dr. Hedrick and colleagues at La Jolla Institute for Allergy and Immunology, University of Virginia, and

Medical College of Wisconsin show that *Abcg1* influences the development of atherosclerosis by affecting regulatory T cell (Treg) development. Furthermore the authors observed that

absence of Abcg1 in Tregs alone is sufficient to drive atheroprotection.

[Check it out.](#)


Testimonials



"My experience with iTL has been great. This is a very professional and efficient team. Everything went smoothly throughout the process and we got our mouse model in a very timely manner. I would highly recommend iTL to my colleagues."

-Emily Wu, PhD
University of California, Los Angeles

Did You Know...



... microRNA gene therapy can be used to prevent cancer metastasis? Metastasis is a leading cause of breast cancer mortality and has been a major hurdle for cancer researchers. Gene expression regulation by microRNAs is important in preventing spread of cancer cells. Researchers at Tel-Aviv

University and MIT have shown that microRNA gene therapy and traditional chemotherapy together lead to significant reductions in tumor metastasis and growth, thus promoting improved cancer remission and patient survival rates. Read more [here](#).

Contact Us



Copyright © 2015. All Rights Reserved.
